For the twelve months ended Sep 30, 2026, VolitionRX Limited reported $3.44M of revenue and -$24.09M of net income.
VNRX revenueQ3 2026$1.61M
- Quarter YoY
- +157.3%
- QoQ
- +304.8%
- FY YoY
- +40.0%
- 5Y CAGR
- +164.1%
VNRX revenue was $1.61M in fiscal Q3 2026 (ended Sep 30, 2026), up 157.3% from a year earlier and up 304.8% from the prior quarter. For the full fiscal 2025 it was $1.73M, up 40.0% from fiscal 2024. Compound annual growth was +164.1% over 5 years. It rose in 5 of the last 6 fiscal years. Fiscal 2025 is the highest of the 10 fiscal years on file.
VNRX net incomeQ3 2026-$3.80M
VNRX net income was -$3.80M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$5.38M a year earlier. For the full fiscal 2025 it was -$23.36M, compared with -$26.97M in fiscal 2024.
VNRX EPSQ3 2026-$0.21
VNRX diluted EPS was -$0.21 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2024 it was -$6.20, compared with -$10.00 in fiscal 2023.
VNRX free cash flowQ3 2026-$4.63M
VNRX free cash flow was -$4.63M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$3.63M a year earlier. For the full fiscal 2025 it was -$19.77M, compared with -$26.17M in fiscal 2024.
Source: XBRL data VolitionRX Limited files with the SEC, latest filing dated Nov 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported May 14, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.